MA54697A - Traitement de la stéatose hépatique - Google Patents

Traitement de la stéatose hépatique

Info

Publication number
MA54697A
MA54697A MA054697A MA54697A MA54697A MA 54697 A MA54697 A MA 54697A MA 054697 A MA054697 A MA 054697A MA 54697 A MA54697 A MA 54697A MA 54697 A MA54697 A MA 54697A
Authority
MA
Morocco
Prior art keywords
treatment
hepatic steatosis
steatosis
hepatic
Prior art date
Application number
MA054697A
Other languages
English (en)
Inventor
Steven B Landau
Christopher R Shepard
Original Assignee
Avogadro Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avogadro Dev Corp filed Critical Avogadro Dev Corp
Publication of MA54697A publication Critical patent/MA54697A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA054697A 2019-01-08 2020-01-08 Traitement de la stéatose hépatique MA54697A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962789874P 2019-01-08 2019-01-08

Publications (1)

Publication Number Publication Date
MA54697A true MA54697A (fr) 2021-11-17

Family

ID=69467750

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054697A MA54697A (fr) 2019-01-08 2020-01-08 Traitement de la stéatose hépatique

Country Status (5)

Country Link
US (1) US20220088050A1 (fr)
EP (1) EP3908287A1 (fr)
CN (1) CN113811312A (fr)
MA (1) MA54697A (fr)
WO (1) WO2020146477A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2677969T3 (es) * 2010-01-08 2018-08-07 Ionis Pharmaceuticals, Inc. Modulación de la expresión tipo angiopoyetina 3
MX340363B (es) * 2010-11-19 2016-07-06 Idera Pharmaceuticals Inc Compuestos de oligonucleotidos inmuno-reguladores (iro) que modulan la respuesta inmune basada en receptores tipo toll.
WO2016149323A1 (fr) * 2015-03-16 2016-09-22 Exicure, Inc. Acides nucléiques sphériques immunomodulateurs
JP2018529726A (ja) * 2015-09-30 2018-10-11 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｔｌｒ調節因子及び使用方法

Also Published As

Publication number Publication date
CN113811312A (zh) 2021-12-17
WO2020146477A1 (fr) 2020-07-16
EP3908287A1 (fr) 2021-11-17
US20220088050A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA47719A (fr) Esketamine pour le traitement de la dépression
DK3411400T3 (da) Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet
IT201700081018A1 (it) Trattamento di segnali elettrofisiologici
MA52219A (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
MA47820A (fr) Traitement de la glycogénose de type iii
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
GB201804514D0 (en) Treatment of pyroptosis
MA46788A (fr) Traitement de la fibrose
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
MA43106A (fr) Traitement de l'oligo-ovulation associée à la stéatose hepatique
MA52216A (fr) Méthodes de traitement de la colite ulcéreuse
DK3548061T3 (da) Behandling af neurologiske sygdomme
MA42999A (fr) Polythérapie pour le traitement de malignités
ES1214135Y (es) Pieza de nivelacion de placas de revestimiento
MA53474A (fr) Distribution de lingettes
MA51525A (fr) Traitement de minéraux
MA42930A (fr) Traitement de maladies neurodégénératives
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
MA55218A (fr) Eskétamine pour le traitement de la dépression
GB201804515D0 (en) Treatment of necroptosis
DK3743064T3 (da) Behandling af proteinuri
GB201805100D0 (en) Treatment of sarcopenic diseases
DK3565592T5 (da) Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
MA56033A (fr) Méthodes de traitement de la sclérodermie généralisée